Tumor mutations and immune activity may reveal who benefits from investigational lymphoma drug
Researchers at the University of Tsukuba conducted a physician-initiated phase 2 clinical trial of dasatinib in patients with relapsed or refractory T-follicular helper cell lymphoma (TFHL), an aggressive and difficult-to-treat blood cancer. The study identified genetic alterations and features of the immune microenvironment associated with treatment response. These findings may help identify…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
